PPARD is a human gene whose product ### transcriptional regulation. Variants in PPARD have been implicated in Neurodegenerative Disorders, Alzheimer's Disease, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Gene Symbol: PPARD
Full Name: Peroxisome Proliferator-Activated Receptor Delta
Other Names: PPARδ, PPAR-beta, NR1C2
Chromosomal Location: 6p21.31
Gene ID: 5468
PPARD belongs to the nuclear hormone receptor superfamily, specifically the peroxisome proliferator-activated receptor (PPAR) subfamily. The family includes three members: PPARA (α), PPARB/PPARD (β/δ), and PPARG (γ)[@michalik2006].
PPARD is a ligand-activated transcription factor containing:
- N-terminal activation function (AF-1) domain
- DNA-binding domain (DBD) with two zinc fingers
- Hinge region
- Ligand-binding domain (LBD) with AF-2 activation function
PPARD is ubiquitously expressed with highest levels in:
- Skeletal muscle
- Brain (cortex, hippocampus, cerebellum)
- Brown adipose tissue
- Liver
- Kidney
In the central nervous system, PPARD is expressed in:
PPARD regulates gene expression by binding to PPAR response elements (PPREs) as a heterodimer with RXR. Target genes are involved in:
- Fatty acid oxidation
- Glucose metabolism
- Lipid metabolism
- Inflammation
- Cell proliferation and differentiation
- Promotes mitochondrial biogenesis
- Enhances fatty acid oxidation in neurons
- Protects against metabolic stress
- Represses pro-inflammatory gene expression
- Inhibits NF-κB signaling
- Modulates microglial activation
- Stimulates neural progenitor cell proliferation
- Promotes differentiation of new neurons
- Supports hippocampal neurogenesis
PPARD activation shows protective effects in AD models[@cheng2020]:
- Reduces amyloid-β toxicity
- Improves mitochondrial function
- Decreases neuroinflammation
- Enhances cognitive performance in animal models
- PPARD agonists protect dopaminergic neurons
- Reduces neuroinflammation in PD models
- Improves mitochondrial function in SNc neurons
- PPARδ (PPARD) dysfunction implicated in HD
- Therapeutic potential of PPARD agonists being explored
- Altered PPARD expression in ALS
- Therapeutic target for metabolic dysfunction
- Dyslipidemia
- Insulin resistance
- Obesity
- Type 2 diabetes
PPARD has complex roles in cancer biology:
- Promotes tumor progression in some contexts
- May have tumor suppressor function in others
Synthetic PPARD agonists (e.g., GW501516, KD3010) have been developed for:
- Metabolic disorders
- Neuroprotection
- Blood-brain barrier penetration important for neurological applications
- Selective modulation to avoid peripheral side effects
PPARD interacts with:
- RXRA (Retinoid X Receptor Alpha)
- PGC-1α (PPARGC1A)
- NCoR (Nuclear Receptor Co-repressor)
- SRC-1 (Nuclear Receptor Coactivator)
- HDAC3
- Peroxisome Proliferator-Activated Receptors
- Neurodegenerative Diseases
- Mitochondrial Biogenesis
- Neuroprotection
- Transcription Factors
- Lipid Metabolism
- Michalik et al., International Union of Basic and Clinical Pharmacology LXIII (2006)
- Cheng et al., PPARδ: A Potential Therapeutic Target for Neurodegenerative Diseases (2020)
- Jiang et al., PPAR-delta is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically (2015)
- Yang et al., Therapeutic Advantages of Dual Targeting of PPAR-delta and PPAR-gamma in an Experimental Model of Sporadic Alzheimer's Disease (2019)
- Lim et al., Erucic acid, a component of Lorenzo's oil and PPAR-delta ligand modifies C6 glioma growth and toxicity of doxorubicin (2017)
- Zhang et al., Activating PPARbeta/delta Protects against Endoplasmic Reticulum Stress-Induced Astrocytic Apoptosis via UCP2-Dependent Mitophagy in Depressive Model (2022)
- Chandra et al., Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease (2016)
- Swanson et al., Peroxisome proliferator-activated receptor γ agonists accelerate oligodendrocyte maturation and influence mitochondrial functions and oscillatory Ca(2+) waves (2011)
- Zhang et al., PPAR agonists for the treatment of neuroinflammatory diseases (2024)
- Liu et al., The role of PPAR in fungal keratitis (2024)
- Cai et al., PPARbeta/delta Agonist Provides Neuroprotection by Suppression of IRE1alpha-Caspase-12-Mediated Endoplasmic Reticulum Stress Pathway in the Rotenone Rat Model of Parkinson's Disease (2016)
- Choi et al., Neuroprotection against Amyloid-beta-Induced DNA Double-Strand Breaks Is Mediated by Multiple Retinoic Acid-Dependent Pathways (2020)
- Park et al., Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics (2025)
- Kim et al., Neuroprotective effects of the PPARbeta/delta antagonist GSK0660 in in vitro and in vivo Parkinson's disease models (2023)
- Hernandez et al., The role of peroxisome proliferator-activated receptors in healthy and diseased eyes (2021)
- Jang et al., PPARbeta/delta activation protects against corticosterone-induced ER stress in astrocytes by inhibiting the CpG hypermethylation of microRNA-181a (2017)
- Goncalves et al., Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs) (2023)
- Lorenzo et al., Role of PPARs in Progression of Anxiety: Literature Analysis and Signaling Pathways Reconstruction (2021)
- Park et al., Peroxisome Proliferator-Activated Receptor-δ Deficiency in Microglia Results in Exacerbated Axonal Injury and Tissue Loss in Experimental Autoimmune Encephalomyelitis (2021)
- Honnami et al., Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ) (2013)
- Goncharov et al., PPARδ agonist GW1516 attenuates inflammation and oxidative stress in experimental traumatic brain injury (2018)
- Yang et al., PPARδ activation ameliorates tau phosphorylation and cognitive deficits in Alzheimer's disease model (2018)